Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4731879 | 0.85 | SCN9A (0.70) | SCN9A | |
| SCHEMBL281707 | 0.83 | SCN9A (1.00) | SCN9A | |
| SCHEMBL4597622 | 0.82 | SCN9A (1.00) | SCN9A | |
| SCHEMBL4596851 | 0.80 | SCN9A (0.75) | SCN9A | |
| SCHEMBL4596006 | 0.80 | SCN9A (0.78) | SCN9A | |
| SCHEMBL4596134 | 0.80 | SCN9A (0.69) | SCN9A | |
| SCHEMBL4727515 | 0.79 | SCN9A (0.77) | SCN9A | |
| SCHEMBL4597888 | 0.78 | SCN9A (0.71) | SCN9A | |
| SCHEMBL4597512 | 0.78 | SCN9A (0.66) | SCN9A | |
| SCHEMBL4596079 | 0.78 | SCN9A (0.74) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103151-A9 | Heterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-05-01 | — | — | US | claimed |
| US-20060258659-A1 | Heterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-16 | — | — | US | claimed |
| US-20080103151-A9 | Heterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-05-01 | — | — | US | disclosed |
| US-20080103151-A9 | Heterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-05-01 | — | — | US | disclosed |
| US-20080103151-A9 | Heterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-05-01 | — | — | US | disclosed |
| WO-2008046082-A2 | USE OF HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1879892-A2 | 2-PYRROLIDONE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND PAIN | XENON PHARMACEUTICALS INC. (CA) | 2008-01-23 | — | — | EP | disclosed |
| US-20060258659-A1 | Heterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-16 | — | — | US | disclosed |
| WO-2006113875-A2 | 2 - PYRROLIDONE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND PAIN | XENON PHARMACEUTICALS INC. (CA) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258659-A1 | Heterocyclic compounds and their uses as therapeutic agents | TRPV1, TRPV3, TRPV5 | SCN9A 83/4885 |
| US-20080103151-A9 | Heterocyclic compounds and their uses as therapeutic agents | TRPV1, TRPV3, TRPV5 | SCN9A 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.